NASDAQ:LENS - Presbia Stock Price, News & Analysis

+0.25 (+357.14 %)
(As of 08/19/2019 12:01 PM ET)
Today's Range
Now: $0.32
50-Day Range
MA: $0.09
52-Week Range
Now: $0.32
Average Volume122,366 shs
Market Capitalization$5.51 million
P/E RatioN/A
Dividend YieldN/A
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:LENS



Sales & Book Value

Annual Sales$20,000.00
Book Value$0.09 per share


Net Income$-8,410,000.00
Net Margins-36,604.35%


Market Cap$5.51 million
Next Earnings DateN/A
OptionableNot Optionable

Receive LENS News and Ratings via Email

Sign-up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter.

Presbia (NASDAQ:LENS) Frequently Asked Questions

What is Presbia's stock symbol?

Presbia trades on the NASDAQ under the ticker symbol "LENS."

How were Presbia's earnings last quarter?

Presbia PLC (NASDAQ:LENS) issued its earnings results on Friday, August, 12th. The medical instruments supplier reported ($0.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.07. The medical instruments supplier had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.04 million. Presbia had a negative return on equity of 414.02% and a negative net margin of 36,604.35%. View Presbia's Earnings History.

What price target have analysts set for LENS?

1 analysts have issued 12-month price objectives for Presbia's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Presbia's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,775.0% from the stock's current price. View Analyst Price Targets for Presbia.

What is the consensus analysts' recommendation for Presbia?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Presbia in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Presbia.

What are Wall Street analysts saying about Presbia stock?

Here are some recent quotes from research analysts about Presbia stock:
  • 1. According to Zacks Investment Research, "Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company's product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. " (9/27/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a discounted cash flow-based net present value (NPV) approach to value Presbia. This yields a total value of $160M for the Flexivue Microlens product, using a 20% discount rate, 50% manufacturing and marketing offset, and a 12.5% tax rate as Presbia is domiciled in Ireland." (8/27/2018)

Has Presbia been receiving favorable news coverage?

Media headlines about LENS stock have been trending negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Presbia earned a news impact score of -2.3 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Presbia.

Who are some of Presbia's key competitors?

What other stocks do shareholders of Presbia own?

Who are Presbia's key executives?

Presbia's management team includes the folowing people:
  • Mr. Vladimir Feingold, Consultant (Age 70)
  • Mr. Mark T. Yung, CEO & Chairman (Age 45)
  • Mr. Valeriano Lima, Corp. Controller, Head of Financial Planning and Analysis & Company Sec. (Age 37)
  • Ms. Casey Jean Lind, Chief Operating Officer (Age 57)
  • Mr. Richard T. Fogarty, Consultant (Age 68)

When did Presbia IPO?

(LENS) raised $50 million in an initial public offering on Thursday, January 29th 2015. The company issued 4,200,000 shares at a price of $11.00-$13.00 per share. Jefferies served as the underwriter for the IPO.

How do I buy shares of Presbia?

Shares of LENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Presbia's stock price today?

One share of LENS stock can currently be purchased for approximately $0.32.

How big of a company is Presbia?

Presbia has a market capitalization of $5.51 million and generates $20,000.00 in revenue each year. Presbia employs 24 workers across the globe.View Additional Information About Presbia.

What is Presbia's official website?

The official website for Presbia is

How can I contact Presbia?

Presbia's mailing address is SANDYFORD OFFICE CENTRE SUITE 7 17 CORRIG ROAD, DUBLIN 18 L2, . The medical instruments supplier can be reached via phone at 353-551-1487.

MarketBeat Community Rating for Presbia (NASDAQ LENS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about Presbia and other stocks. Vote "Outperform" if you believe LENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel